FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yair Lotan

Research Profile

Disorders

Procedures

Chemicals & Drugs

Biological Tumor Markers

Concepts & Ideas

Activities & Behaviors

Co-author Network

Publications

TOP 3
Tori N Sutherland; Margaret S Pearle; Yair Lotan
How Much is a Kidney Worth? Cost-Effectiveness of Routine Imaging After Ureteroscopy to Prevent Silent Obstruction.
Aditya Bagrodia; Karim Bensalah; Ithaar H Derweesh; Bishoy A Gayed; Payal Kapur; Franklin E Kuehhas; Yair Lotan; Jay D Raman; Arthur I Sagalowsky; Shahrokh F Shariat; Christopher G Wood; Vitaly Margulis
Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma.
Christian Bolenz; Wareef Kabbani; Nicolas Ortiz; Ann Marie West; Yair Lotan
Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yair Lotan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Tori N Sutherland; Margaret S Pearle; Yair Lotan
How Much is a Kidney Worth? Cost-Effectiveness of Routine Imaging After Ureteroscopy to Prevent Silent Obstruction.
The Journal of urology 2013;189(6):2136-41.
2013: Aditya Bagrodia; Karim Bensalah; Ithaar H Derweesh; Bishoy A Gayed; Payal Kapur; Franklin E Kuehhas; Yair Lotan; Jay D Raman; Arthur I Sagalowsky; Shahrokh F Shariat; Christopher G Wood; Vitaly Margulis
Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma.
Urology 2013;81(5):972-8.
2013: Christian Bolenz; Wareef Kabbani; Nicolas Ortiz; Ann Marie West; Yair Lotan
Urinary cytology for the detection of urothelial carcinoma of the bladder--a flawed adjunct to cystoscopy?
Urologic oncology 2013;31(3):366-71.
2013: Aditya Bagrodia; Yair Lotan
Words of Wisdom: re: radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
European urology 2013;63(3):580-1.
2013: Oussama M Darwish; Payal Kapur; Yair Lotan; Feras Alhalabi; Aditya Bagrodia; Michael Belsante; Arthur I Sagalowsky; Ramy F Youssef; Vitaly Margulis
Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.
Urology 2013;81(3):581-6.
2013: Yair Lotan; L Molinier; I Buendia Jiménez; Michel Daudon; Irene Lenoir-Wijnkoop; I Tack; M J C Nuijten
Increased water intake as a prevention strategy for recurrent urolithiasis: major impact of compliance on cost-effectiveness.
The Journal of urology 2013;189(3):935-9.
2013: Mehrad Adibi; Deepa Bhat; Brad Hornberger; Ganesh Raj; Claus G Roehrborn; Yair Lotan
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis.
The Journal of urology 2013;189(2):535-40.
2013: Ashish M Kamat; Peter E Clark; Michael Droller; Jason R Gee; Nicholas Hegarty; Paul K Hegarty; Lawrence C Jenkins; Yair Lotan; Bernd J Schmitz-Dräger; Shahrokh F Shariat; Robert S Svatek; Bas W G van Rhijn; evanguelos xylinas; Pierre I Karakiewicz
ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers.
European urology 2013;63(1):4-15.
2012: Yair Lotan
Editorial comment.
The Journal of urology 2012;188(6):2203; discussion 2203-4.
2012: Christopher A Rippel; Ramy F Youssef; Zeeshan Danawala; Yu Kuan Lin; Yair Lotan; Lucas Nikkel; Vincent Olorunnisomo; Margaret S Pearle; Jay D Raman
Residual fragments following ureteroscopic lithotripsy: incidence and predictors on postoperative computerized tomography.
The Journal of urology 2012;188(6):2246-51.
2012: Mehrad Adibi; Christian Bolenz; Yair Lotan; Francesco Montorsi; Arthur I Sagalowsky; Shahrokh F Shariat; Christopher G Wood; Ramy Youssef; Richard Zigeuner; Vitaly Margulis
Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades.
International journal of urology : official journal of the Japanese Urological Association 2012;19(12):1060-6.
2012: Yair Lotan; Laurent Molinier; Inmaculada Buendia Jiménez; Michel Daudon; Irene Lenoir-Wijnkoop; Ivan Tack; Mark J C Nuijten
Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
BJU international 2012;110(11 Pt C):E1060-7.
2012: Aditya Bagrodia; Karen Delafuente; Varun Rachakonda; Claus G Roehrborn; Joseph Scales; Suzette Toombs; Owen Yeh; Yair Lotan
Surgeon fatigue: impact of case order on perioperative parameters and patient outcomes.
The Journal of urology 2012;188(4):1291-6.
2012: Matthew E Nielsen; Raj S Pruthi; Neal Shore; Angela B Smith; Gilad Amiel; THOMAS GUZZO; Yair Lotan
Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
BJU international 2012;110(7):967-72.
2012: Ramy Youssef; Ahmed Mosbah; Shahrokh F Shariat; Hassan Abol-Enein; Tyler Arendt; Mohamed Ghoneim; Wareef Kabbani; Payal Kapur; Yair Lotan
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
BJU international 2012;110(7):961-6.
2012: Yair Lotan
Words of wisdom. Re: Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.
European urology 2012;62(2):352-3.
2012: Casey A Seideman; Joshua P Sleeper; Yair Lotan
Cost comparison of robot-assisted and laparoscopic pyeloplasty.
Journal of endourology / Endourological Society 2012;26(8):1044-8.
2012: Samuel Peña-Llopis; Mark T Ross; Arthur I Sagalowsky; Sharanya Sivanand; Patrick Spence; Pia Banerji Summerour; Silvia Vega-Rubín-de-Celis; Shanshan Wang; S W Wendy Wong; Xian-Jin Xie; Toshinari Yamasaki; Leah Zhrebker; Nick Grishin; Tina Hambuch; Christian D Haudenschild; Suneer Jain; Wareef Kabbani; Payal Kapur; Lisa Kinch; Marc Laurent; Nan Leng; Arnold Liao; Yair Lotan; Vitaly Margulis; Andrea Pavía-Jiménez; David R Bentley; James Brugarolas
BAP1 loss defines a new class of renal cell carcinoma.
Nature genetics 2012;44(7):751-9.
2012: Aditya Bagrodia; Michael J Belsante; Chase Cannon; Oussama M Darwish; Deniz Gerecci; Payal Kapur; Yair Lotan; Arthur I Sagalowsky; Shahrokh F Shariat; Ramy F Youssef; Vitaly Margulis
Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma.
European urology 2012;62(1):e27-9.
2012: Mehrad Adibi; Margaret S Pearle; Yair Lotan
Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis.
BJU international 2012;110(2 Pt 2):E86-91.
2012: Sharanya Sivanand; Patrick Spence; Noelle S Williams; Nicholas C Wolff; Xian-Jin Xie; Toshinari Yamasaki; Hong Zhao; David R Bentley; Jeffrey A Cadeddu; Jessica Gillen; Wareef Kabbani; Payal Kapur; Blanka Kucejova; Yair Lotan; Vitaly Margulis; David J McBride; Lorraine Morlock; Andrea Pavia-Jimenez; Samuel Peña-Llopis; Ganesh V Raj; Mark T Ross; Arthur Sagalowsky; James Brugarolas
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.
Science translational medicine 2012;4(137):137ra75.
2012: Yair Lotan; Shahrokh F Shariat; Robert S Svatek; Catherine M Tangen; Ian M Thompson; Ramy F Youssef; Phyllis J Goodman; Eric A Klein
Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT.
The Journal of urology 2012;187(6):2005-10.
2012: Yair Lotan
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.
Cancer 2012;118(10):2566-7.
2012: Yair Lotan
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con.
The Journal of urology 2012;187(5):1538-9.
2012: Ramy F Youssef; Raheela Ashfaq; Richard Ho; Arthur I Sagalowsky; Bruce J Schlomer; Yair Lotan
Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.
Urologic oncology 2012;30(3):273-7.
2012: Thomas Clements; Scott E Eggener; Michael P Herman; Yair Lotan; Steven M Lucas; Jamie C Messer; Casey K Ng; Douglas S Scherr; Benjamin Scoll; Shahrokh F Shariat; John D Terrell; Robert G Uzzo; Mark Wille; Stephen A Boorjian; Jay D Raman
High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection.
Journal of endourology / Endourological Society 2012;26(4):398-402.
2012: Yair Lotan
Is robotic surgery cost-effective: no.
Current opinion in urology 2012;22(1):66-9.
2011: Ramy F Youssef; Richard Zigeuner; Christian Bolenz; Charles C Guo; Wareef Kabbani; Wassim Kassouf; Eiji Kikuchi; Cord Langner; Yair Lotan; Francesco Montorsi; Jay D Raman; Mesut Remzi; Marco Roscigno; Arthur I Sagalowsky; Shahrokh F Shariat; Alon Z Weizer; Christopher G Wood; Vitaly Margulis
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.
BJU international 2011;108(8):1286-91.
2011: Blanka Kucejova; Yair Lotan; Samuel Peña-Llopis; Sharanya Sivanand; Tram Anh T Tran; Nicholas C Wolff; Xian-Jin Xie; Toshinari Yamasaki; Shane Alexander; Wareef Kabbani; Payal Kapur; James Brugarolas
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
Molecular cancer research : MCR 2011;9(9):1255-65.
2011: Jamie Messer; Casey K Ng; Stephen A Boorjian; James C Brien; Scott E Eggener; Michael P Herman; Yair Lotan; Steven M Lucas; Douglas S Scherr; Benjamin Scoll; Shahrokh F Shariat; Gary Steinberg; John D Terrell; Robert G Uzzo; Mark Wille; Jay D Raman
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.
BJU international 2011;108(5):701-5.
2011: Yair Lotan; Margaret S Pearle
Cost-effectiveness of primary prevention strategies for nephrolithiasis.
The Journal of urology 2011;186(2):550-5.
2011: Woonbok Chung; Bogdan Czerniak; Jaroslav Jelinek; Shoudan Liang; Yair Lotan; Jolanta Bondaruk; Jean-Pierre J Issa
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011;20(7):1483-91.
2011: Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2020-6.
2011: Christian Bolenz; Amit Gupta; Claus G Roehrborn; Yair Lotan
Predictors of costs for robotic-assisted laparoscopic radical prostatectomy.
Urologic oncology 2011;29(3):325-9.
2011: Yair Lotan
The future of nephron sparing procedures for renal masses: balancing costs, efficacy, patient outcomes and experience.
The Journal of urology 2011;185(5):1560-1.
2011: Cenk Gurbuz; Ramy F Youssef; Shahrokh F Shariat; Yair Lotan; Christopher G Wood; Arthur I Sagalowsky; Richard Zigeuner; Eiji Kikuchi; Alon Z Weizer; Jay D Raman; Mesut Remzi; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Wassim Kassouf; Vitaly Margulis
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma.
Journal of endourology / Endourological Society 2011;25(5):775-9.
2011: Ramy F Youssef; Shahrokh F Shariat; Yair Lotan; Christopher G Wood; Arthur I Sagalowsky; Richard Zigeuner; Cord Langner; Francesco Montorsi; Christian Bolenz; Vitaly Margulis
Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma.
Urology 2011;77(4):861-6.
2011: Sunshine Murray; Rashel M Haverkorn; Yair Lotan; Gary E Lemack
Mesh kits for anterior vaginal prolapse are not cost effective.
International urogynecology journal 2011;22(4):447-52.
2011: Chester J Donnally; Amit Gupta; Karim Bensalah; Altug Tuncel; Jay Raman; Margaret S Pearle; Yair Lotan
Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones.
Urological research 2011;39(2):141-6.
2011: Ramy F Youssef; Shahrokh F Shariat; Payal Kapur; Wareef Kabbani; Ahmed Mosbah; Hassan Abol-Enein; Mohamed Ghoniem; Yair Lotan
Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder.
The Journal of urology 2011;185(3):1112-7.
2011: Saad A Mir; Jeffrey A Cadeddu; Joshua P Sleeper; Yair Lotan
Cost comparison of robotic, laparoscopic, and open partial nephrectomy.
Journal of endourology / Endourological Society 2011;25(3):447-53.
2011: L Erickstad; G Reed; D Bhat; Claus G Roehrborn; Yair Lotan
Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution.
Prostate cancer and prostatic diseases 2011;14(1):85-9.
2011: Ramy F Youssef; Shahrokh F Shariat; Payal Kapur; Wareef Kabbani; Tarek Ghoneim; Ellen King; Amber Cockburn; Ahmed Mosbah; Hassan Abol-Enein; Mohamed Ghoneim; Yair Lotan
Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
Human pathology 2011;42(3):347-55.
2011: Robert S Svatek; Yair Lotan
Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Cancer prevention research (Philadelphia, Pa.) 2011;4(2):277-83.
2011: Ganesh V Raj; Saumil Karavadia; Bruce Schlomer; Yull Arriaga; Yair Lotan; Arthur I Sagalowsky; Eugene Frenkel
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Cancer 2011;117(2):276-82.
2011: Yair Lotan
Editorial comment.
Urology 2011;77(1):159.
2010: Christian Bolenz; Richard Ho; Geoffrey R Nuss; Nicolas Ortiz; Ganesh V Raj; Arthur I Sagalowsky; Yair Lotan
Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival.
BJU international 2010;106(9):1324-9.
2010: Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn; Yair Lotan
The influence of body mass index on the cost of radical prostatectomy for prostate cancer.
BJU international 2010;106(8):1188-93.
2010: Christian Bolenz; Shahrokh F Shariat; Pierre I Karakiewicz; Raheela Ashfaq; Richard Ho; Arthur I Sagalowsky; Yair Lotan
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder.
BJU international 2010;106(8):1216-22.
2010: Christian Bolenz; Yair Lotan
Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers.
Cancer biology & therapy 2010;10(5):407-15.
2010: Yair Lotan
Editorial comment.
Urology 2010;76(2):396-7.
2010: Vitaly Margulis; Ramy F Youssef; Pierre I Karakiewicz; Yair Lotan; Christopher G Wood; Richard Zigeuner; Eiji Kikuchi; Alon Z Weizer; Jay D Raman; Mesut Remzi; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Wassim Kassouf; Shahrokh F Shariat
Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract.
The Journal of urology 2010;184(2):453-8.
2010: Yair Lotan; Shahrokh F Shariat; Bernd J Schmitz-Dräger; Marta Sanchez-Carbayo; Feliksas Jankevicius; Marco Racioppi; Sarah J P Minner; Brigitte Stöhr; Pier Francesco Bassi; H Barton Grossman
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.
Urologic oncology 2010;28(4):441-8.
2010: Keren Elias; Robert S Svatek; Samir Gupta; Richard Ho; Yair Lotan
High-risk patients with hematuria are not evaluated according to guideline recommendations.
Cancer 2010;116(12):2954-9.
2010: Yair Lotan
Words of wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
European urology 2010;57(6):1116-7.
2010: Yair Lotan
Editorial comment.
Urology 2010;75(6):1282; author reply 1282-3.
2010: Shahrokh F Shariat; Guilherme Godoy; Yair Lotan; Michael Droller; Pierre I Karakiewicz; Jay D Raman; Hendrik Isbarn; Alon Z Weizer; Mesut Remzi; Marco Roscigno; Eiji Kikuchi; Christian Bolenz; Karim Bensalah; Theresa Koppie; Wassim Kassouf; Jeffrey C Wheat; Richard Zigeuner; Cord Langner; Christopher G Wood; Vitaly Margulis
Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy.
BJU international 2010;105(12):1672-7.
2010: Yair Lotan; Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn
The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons.
BJU international 2010;105(11):1531-5.
2010: Shahrokh F Shariat; Ramy F Youssef; Amit Gupta; Daher C Chade; Pierre I Karakiewicz; Hendrik Isbarn; Claudio Jeldres; Arthur I Sagalowsky; Raheela Ashfaq; Yair Lotan
Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
The Journal of urology 2010;183(5):1744-50.
2010: Shahrokh F Shariat; Robert S Svatek; Derya Tilki; Eila Skinner; Pierre I Karakiewicz; Umberto Capitanio; Patrick J Bastian; Bjoern G Volkmer; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Jonathan I Izawa; Vincenzo Ficarra; Seth P Lerner; Arthur I Sagalowsky; Mark P Schoenberg; Ashish M Kamat; Colin P Dinney; Yair Lotan; Michael J Marberger; Yves Fradet
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
BJU international 2010;105(10):1402-12.
2010: Yair Lotan
Editorial comment.
The Journal of urology 2010;183(4):1372.
2010: Christian Bolenz; Amit Gupta; Timothy Hotze; Richard Ho; Jeffrey A Cadeddu; Claus G Roehrborn; Yair Lotan
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
European urology 2010;57(3):453-8.
2010: Matthias Waldert; Pierre I Karakiewicz; Jay D Raman; Mesut Remzi; Hendrik Isbarn; Yair Lotan; umberto capitanio; Karim Bensalah; Michael J Marberger; Shahrokh F Shariat
A delay in radical nephroureterectomy can lead to upstaging.
BJU international 2010;105(6):812-7.
2010: Shahrokh F Shariat; Christian Bolenz; Pierre I Karakiewicz; Yves Fradet; Raheela Ashfaq; Patrick J Bastian; Matthew Nielsen; Umberto Capitanio; Claudio Jeldres; Jérôme Rigaud; Stefan C Müller; Seth P Lerner; Francesco Montorsi; Arthur I Sagalowsky; Richard J Cote; Yair Lotan
p53 expression in patients with advanced urothelial cancer of the urinary bladder.
BJU international 2010;105(4):489-95.
2010: Yair Lotan
Role of biomarkers to predict outcomes and response to therapy.
Urologic oncology 2010;28(1):97-101.
2010: Bruce J Schlomer; Richard Ho; Arthur I Sagalowsky; Raheela Ashfaq; Yair Lotan
Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
The Journal of urology 2010;183(1):62-7.
2010: Jay D Raman; Aditya Bagrodia; Karim Bensalah; Margaret S Pearle; Yair Lotan
Residual fragments after percutaneous nephrolithotomy: cost comparison of immediate second look flexible nephroscopy versus expectant management.
The Journal of urology 2010;183(1):188-93.
2010: Shahrokh F Shariat; Daher C Chade; Pierre I Karakiewicz; Raheela Ashfaq; Hendrik Isbarn; Yves Fradet; Patrick J Bastian; Matthew Nielsen; Umberto Capitanio; Claudio Jeldres; Francesco Montorsi; Seth P Lerner; Arthur I Sagalowsky; Richard J Cote; Yair Lotan
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
The Journal of urology 2010;183(1):68-75.
2010: Yair Lotan
Economics of robotics in urology.
Current opinion in urology 2010;20(1):92-7.
2009: Christian Bolenz; Yair Lotan; Raheela Ashfaq; Shahrokh F Shariat
Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder.
European urology 2009;56(6):1093-5.
2009: Yair Lotan
Editorial comment on: Serum proteomic profiling in patients with bladder cancer.
European urology 2009;56(6):996-7.
2009: Shahrokh F Shariat; Pierre I Karakiewicz; Guilherme Godoy; Jose A Karam; Raheela Ashfaq; Yves Fradet; Hendrik Isbarn; Francesco Montorsi; Claudio Jeldres; Patrick J Bastian; Matthew Nielsen; Stefan C Müller; Arthur I Sagalowsky; Yair Lotan
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7012-9.
2009: Yair Lotan; Ashish M Kamat; Michael P Porter; Victoria L Robinson; Neal Shore; Michael Jewett; Paul F Schelhammer; Ralph W deVere White; Diane Quale; Cheryl T Lee
Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.
Cancer 2009;115(18):4096-103.
2009: Karim Bensalah; Altug Tuncel; Jay D Raman; Aditya Bagrodia; Margaret Pearle; Yair Lotan
How physician and patient perceptions differ regarding medical management of stone disease.
The Journal of urology 2009;182(3):998-1004.
2009: Shahrokh F Shariat; Yair Lotan; Pierre I Karakiewicz; Raheela Ashfaq; Hendrik Isbarn; Yves Fradet; Patrick J Bastian; Matthew Nielsen; Umberto Capitanio; Claudio Jeldres; Francesco Montorsi; Stefan C Müller; Jose A Karam; Lukas Heukamp; GEORGES NETTO; Seth P Lerner; Arthur I Sagalowsky; Richard J Cote
p53 predictive value for pT1-2 N0 disease at radical cystectomy.
The Journal of urology 2009;182(3):907-13.
2009: Joshua M Stern; Amit Gupta; Jay D Raman; Nicholas Cost; Steven Lucas; Yair Lotan; Ganesh V Raj; Jeffrey A Cadeddu
Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome.
BJU international 2009;104(6):786-9.
2009: Aditya Bagrodia; Amit Gupta; Jay D Raman; Karim Bensalah; Margaret S Pearle; Yair Lotan
Predictors of cost and clinical outcomes of percutaneous nephrostolithotomy.
The Journal of urology 2009;182(2):586-90.
2009: Hendrik Isbarn; Pierre I Karakiewicz; Shahrokh F Shariat; umberto capitanio; Ganesh S Palapattu; Arthur I Sagalowsky; Yair Lotan; Mark P Schoenberg; Gilad E Amiel; Seth P Lerner; Guru Sonpavde
Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
The Journal of urology 2009;182(2):459-65; discussion 465.
2009: Aditya Bagrodia; Sonal Grover; Srivastava Abhishek; Amit Gupta; Christian Bolenz; Arthur I Sagalowsky; Yair Lotan
Impact of body mass index on clinical and cost outcomes after radical cystectomy.
BJU international 2009;104(3):326-30.
2009: Yair Lotan
Re: JSLS. 2008;12(1):9-12 A da Vinci robot system can make sense for a mature laparoscopic prostatectomy program.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2009;13(3):465; author reply 465-6.
2009: Amit Gupta; Jay D Raman; Raymond J Leveillee; Marshall S Wingo; Ilia S Zeltser; Yair Lotan; Clayton Trimmer; Joshua M Stern; Jeffrey A Cadeddu
General anesthesia and contrast-enhanced computed tomography to optimize renal percutaneous radiofrequency ablation: multi-institutional intermediate-term results.
Journal of endourology / Endourological Society 2009;23(7):1099-105.
2009: Yair Lotan; Keren Elias; Robert S Svatek; Aditya Bagrodia; Geoffrey Nuss; Brett Moran; Arthur I Sagalowsky
Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
The Journal of urology 2009;182(1):52-7; discussion 58.
2009: Shahrokh F Shariat; Christian Bolenz; Guilherme Godoy; Yves Fradet; Raheela Ashfaq; Pierre I Karakiewicz; Hendrik Isbarn; Claudio Jeldres; Jérôme Rigaud; Arthur I Sagalowsky; Yair Lotan
Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
The Journal of urology 2009;182(1):78-84; discussion 84.
2009: Marco Roscigno; Shahrokh F Shariat; Vitaly Margulis; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Cord Langner; Yair Lotan; Alon Z Weizer; Karim Bensalah; Jay D Raman; Christian Bolenz; Charles C Guo; Christopher G Wood; Richard Zigeuner; Jeffrey Wheat; Wareef Kabbani; Theresa Koppie; Casey Ng; Nazareno Suardi; Roberto Bertini; Mario I Fernández; Shuji Mikami; Masaru Isida; Maurice Stephan Michel; Francesco Montorsi
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
The Journal of urology 2009;181(6):2482-9.
2009: Yair Lotan
Words of wisdom. Re: Evaluating the learning curve for robot- assisted laparoscopic radical cystectomy.
European urology 2009;55(5):1237-9.
2009: Yair Lotan; umberto capitanio; Shahrokh F Shariat; Georg C Hutterer; Pierre I Karakiewicz
Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
BJU international 2009;103(10):1368-74.
2009: umberto capitanio; Nazareno Suardi; Shahrokh F Shariat; Yair Lotan; Ganesh S Palapattu; Patrick J Bastian; Amit Gupta; Amnon Vazina; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Pierre I Karakiewicz
Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer.
BJU international 2009;103(10):1359-62.
2009: Amit Gupta; Yair Lotan; Raheela Ashfaq; Claus G Roehrborn; Ganesh V Raj; Corinne C Aragaki; Francesco Montorsi; Shahrokh F Shariat
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
European urology 2009;55(5):1124-33.
2009: Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Z Weizer; Jay D Raman; Christopher G Wood
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.
Cancer 2009;115(6):1224-33.
2009: Jay D Raman; Aditya Bagrodia; Amit Gupta; Karim Bensalah; Jeffrey A Cadeddu; Yair Lotan; Margaret S Pearle
Natural history of residual fragments following percutaneous nephrostolithotomy.
The Journal of urology 2009;181(3):1163-8.
2009: Christian Bolenz; Shahrokh F Shariat; Mario I Fernández; Vitaly Margulis; Yair Lotan; Pierre Karakiewicz; Mesut Remzi; Eiji Kikuchi; Richard Zigeuner; Alon Z Weizer; Francesco Montorsi; Karim Bensalah; Christopher G Wood; Marco Roscigno; Cord Langner; Theresa Koppie; Jay D Raman; Shuji Mikami; Maurice Stephan Michel; Philipp Ströbel
Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density.
BJU international 2009;103(3):302-6.
2009: Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Z Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey Ng; Mario Fernández; Theresa Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat
Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.
BJU international 2009;103(3):307-11.
2008: Amit Gupta; Pierre I Karakiewicz; Claus G Roehrborn; Yair Lotan; Alexandre R Zlotta; Shahrokh F Shariat
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7385-90.
2008: Steven M Lucas; Geoffrey Nuss; Joshua Stern; Yair Lotan; Arthur I Sagalowsky; Jeffrey A Cadeddu; Ganesh V Raj
The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses.
Cancer 2008;113(10):2681-6.
2008: Hong-Seok Park; Weon Seo Park; Jolanta Bondaruk; Noriyoshi Tanaka; Hiroshi Katayama; Sangkyou Lee; Philippe E Spiess; Jordan R Steinberg; Zhi Wang; Ruth Katz; Colin P N Dinney; Keren J Elias; Yair Lotan; Rizwan C. Naeem; Keith A Baggerly; Subrata Sen; H Barton Grossman; Bogdan Czerniak
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Journal of the National Cancer Institute 2008;100(19):1401-11.
2008: Aditya Bagrodia; Amit Gupta; Jay D Raman; Karim Bensalah; Margaret S Pearle; Yair Lotan
Impact of body mass index on cost and clinical outcomes after percutaneous nephrostolithotomy.
Urology 2008;72(4):756-60.
2008: Robert S Svatek; Yair Lotan
Is there a rationale for bladder cancer screening?
Current urology reports 2008;9(5):339-41.
2008: Yair Lotan; Aditya Bagrodia; Claus G Roehrborn; Jan Scott
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier?
Urology 2008;72(3):494-7.
2008: James Brugarolas; Yair Lotan; Lori Watumull; Wareef Kabbani
Sirolimus in metatastic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3457-60.
2008: Steven M Lucas; Robert S Svatek; Guadencio Olgin; Yull Arriaga; Wareef Kabbani; Arthur I Sagalowsky; Yair Lotan
Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery.
BJU international 2008;102(2):172-6.
2008: Vitaly Margulis; Yair Lotan; Francesco Montorsi; Shahrokh F Shariat
Predicting survival after radical cystectomy for bladder cancer.
BJU international 2008;102(1):15-22.
2008: Shahrokh F Shariat; Vitaly Margulis; Yair Lotan; Francesco Montorsi; Pierre I Karakiewicz
Nomograms for bladder cancer.
European urology 2008;54(1):41-53.
2008: Jochen Walz; Shahrokh F Shariat; Nazareno Suardi; Paul Perrotte; Yair Lotan; Ganesh S Palapattu; Amit Gupta; Patrick J Bastian; Craig G Rogers; Amnon Vazina; Gilad E Amiel; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner; Pierre I Karakiewicz
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
BJU international 2008;101(11):1356-61.
2008: Yair Lotan; Karim Bensalah; Timothy Ruddell; Shahrokh F Shariat; Arthur I Sagalowsky; Raheela Ashfaq
Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
The Journal of urology 2008;179(6):2164-9.
2008: Karim Bensalah; Altug Tuncel; Amit Gupta; Jay D Raman; Margaret S Pearle; Yair Lotan
Determinants of quality of life for patients with kidney stones.
The Journal of urology 2008;179(6):2238-43; discussion 2243.
2008: Yair Lotan; Shahrokh F Shariat
Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.
BJU international 2008;101(11):1362-7.
2008: Karim Bensalah; Jay D Raman; Aditya Bagrodia; Andrea Marvin; Yair Lotan
Does obesity impact the costs of partial and radical nephrectomy?
The Journal of urology 2008;179(5):1714-7; discussion 1717-8.
2008: Jay D Raman; James Thomas; Steven M Lucas; Karim Bensalah; Yair Lotan; Clayton Trimmer; Jeffrey A Cadeddu
Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes.
The Canadian journal of urology 2008;15(2):3980-5.
2008: Georg C Hutterer; Pierre I Karakiewicz; Craig D Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Vincenzo Serretta; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Paul Perrotte; Yair Lotan; Michael J Marberger; Shahrokh F Shariat
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
BJU international 2008;101(5):561-5.
2008: Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Cancer 2008;112(5):1058-65.
2008: Yair Lotan
Editorial comment on: Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
European urology 2008;53(3):579-80.
2008: Amit Gupta; Yair Lotan; Patrick J Bastian; Ganesh S Palapattu; Pierre I Karakiewicz; Ganesh V Raj; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Shahrokh F Shariat
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
Urology 2008;71(2):302-7.
2008: Yair Lotan; Robert S Svatek; Núria Malats
Screening for bladder cancer: a perspective.
World journal of urology 2008;26(1):13-8.
2008: Vitaly Margulis; Yair Lotan; Shahrokh F Shariat
Survivin: a promising biomarker for detection and prognosis of bladder cancer.
World journal of urology 2008;26(1):59-65.
2008: Karim Bensalah; Ilia S Zeltser; Altug Tuncel; Jeffrey A Cadeddu; Yair Lotan
Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours.
BJU international 2008;101(4):467-71.
2008: Karim Bensalah; Margaret S Pearle; Yair Lotan
Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones.
European urology 2008;53(2):411-8.
2008: Patrick J Bastian; Georg C Hutterer; Shahrokh F Shariat; Craig G Rogers; Ganesh S Palapattu; Yair Lotan; Amnon Vazina; Gilad E Amiel; Amit Gupta; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg; Pierre I Karakiewicz
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.
BJU international 2008;101(4):450-4.
2008: Shahrokh F Shariat; Pierre I Karakiewicz; Raheela Ashfaq; Seth P Lerner; Ganesh S Palapattu; Richard J Cote; Arthur I Sagalowsky; Yair Lotan
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
Cancer 2008;112(2):315-25.
2008: Yair Lotan; Reuben Lotan
Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: a promising strategy?
Cancer biology & therapy 2008;7(1):101-2.
2008: Karim Bensalah; Yair Lotan; Jose A Karam; Shahrokh F Shariat
New circulating biomarkers for prostate cancer.
Prostate cancer and prostatic diseases 2008;11(2):112-20.
2008: Shahrokh F Shariat; Robert S Svatek; Wareef Kabbani; Jochen Walz; Yair Lotan; Pierre I Karakiewicz; Claus G Roehrborn
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
BJU international 2008;101(2):232-7.
2007: Yair Lotan; Robert S Svatek
Cost-effectiveness of bladder cancer screening.
Expert review of pharmacoeconomics & outcomes research 2007;7(6):627-32.
2007: Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Urologic oncology 2007;25(6):468-75.
2007: Matthew Nielsen; Ganesh S Palapattu; Pierre I Karakiewicz; Yair Lotan; Patrick J Bastian; Seth P Lerner; Arthur I Sagalowsky; Mark P Schoenberg; Shahrokh F Shariat
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome.
BJU international 2007;100(5):1015-20.
2007: Shahrokh F Shariat; Karim Bensalah; Jose A Karam; Claus G Roehrborn; Andrea Gallina; Yair Lotan; Kevin Slawin; Pierre I Karakiewicz
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5377-84.
2007: Jose A Karam; Yair Lotan; Raheela Ashfaq; Arthur I Sagalowsky; Shahrokh F Shariat
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Urology 2007;70(3):482-6.
2007: Joshua M Stern; Jennifer Stanfield; Yair Lotan; Sangtae Park; Jer-Tsong Hsieh; Jeffrey A Cadeddu
Efficacy of laser-activated gold nanoshells in ablating prostate cancer cells in vitro.
Journal of endourology / Endourological Society 2007;21(8):939-43.
2007: Lance P Walsh; J Kyle Anderson; Meredith R Baker; Bumsoo Han; Jer-Tsong Hsieh; Yair Lotan; Jeffrey A Cadeddu
In vitro assessment of the efficacy of thermal therapy in human renal cell carcinoma.
Urology 2007;70(2):380-4.
2007: Yair Lotan; Margaret S Pearle
Economics of stone management.
The Urologic clinics of North America 2007;34(3):443-53.
2007: Yair Lotan
Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
European urology 2007;52(2):453-4.
2007: Jose A Karam; Shahrokh F Shariat; Hong-Ying Huang; Rey-Chen Pong; Raheela Ashfaq; Ellen Shapiro; Yair Lotan; Arthur I Sagalowsky; Xue-Ru Wu; Jer-Tsong Hsieh
Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4400-6.
2007: Joshua M Stern; Robert S Svatek; Sangtae Park; Michael Hermann; Yair Lotan; Arthur I Sagalowsky; Jeffrey A Cadeddu
Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours.
BJU international 2007;100(2):287-90.
2007: Jose A Karam; Yair Lotan; Claus G Roehrborn; Raheela Ashfaq; Pierre I Karakiewicz; Shahrokh F Shariat
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
The Prostate 2007;67(6):614-22.
2007: Shahrokh F Shariat; Alexandre R Zlotta; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(4):445-59.
2007: Shahrokh F Shariat; Raheela Ashfaq; Pierre I Karakiewicz; Osamah Saeedi; Arthur I Sagalowsky; Yair Lotan
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
Cancer 2007;109(6):1106-13.
2007: Vitaly Margulis; Shahrokh F Shariat; Raheela Ashfaq; Melissa Thompson; Arthur I Sagalowsky; Jer-Tsong Hsieh; Yair Lotan
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
The Journal of urology 2007;177(3):1163-8.
2007: Matthew Nielsen; Shahrokh F Shariat; Pierre I Karakiewicz; Yair Lotan; Craig G Rogers; Gilad E Amiel; Patrick J Bastian; Amnon Vazina; Amit Gupta; Seth P Lerner; Arthur I Sagalowsky; Mark P Schoenberg; Ganesh S Palapattu
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy.
European urology 2007;51(3):699-706; discussion 706-8.
2007: Jose A Karam; Yair Lotan; Pierre I Karakiewicz; Raheela Ashfaq; Arthur I Sagalowsky; Claus G Roehrborn; Shahrokh F Shariat
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.
The lancet oncology 2007;8(2):128-36.
2007: Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
The Journal of urology 2007;177(2):481-7; discussion 487.
2007: Sangtae Park; Omar Jaffer; Yair Lotan; Hossein Saboorian; Claus G Roehrborn; Jeffrey A Cadeddu
Contemporary laparoscopic and open radical retropubic prostatectomy: pathologic outcomes and Kattan postoperative nomograms are equivalent.
Urology 2007;69(1):118-22.
2007: Shahrokh F Shariat; Ganesh S Palapattu; Pierre I Karakiewicz; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Yair Lotan
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy.
European urology 2007;51(1):152-60.
2007: Shahrokh F Shariat; Ganesh S Palapattu; Pierre I Karakiewicz; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Yair Lotan
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy.
European urology 2007;51(1):137-49; discussion 149-51.
2006: Vitaly Margulis; Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7369-73.
2006: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
The Journal of urology 2006;176(6 Pt 1):2414-22; discussion 2422.
2006: Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
Human pathology 2006;37(12):1568-76.
2006: Pierre I Karakiewicz; Shahrokh F Shariat; Ganesh S Palapattu; Paul Perrotte; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner
Precystectomy nomogram for prediction of advanced bladder cancer stage.
European urology 2006;50(6):1254-60; discussion 1261-2.
2006: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Gilad E Amiel; Yair Lotan; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Amit Gupta; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner
Nomograms provide improved accuracy for predicting survival after radical cystectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6663-76.
2006: Joshua M Stern; J Kyle Anderson; Yair Lotan; Sangtae Park; Jeffrey A Cadeddu
Nicotinamide adenine dinucleotide staining immediately following radio frequency ablation of renal tumors-is a positive stain synonymous with ablative failure?
The Journal of urology 2006;176(5):1969-72; discussion 1972.
2006: Pierre I Karakiewicz; Shahrokh F Shariat; Ganesh S Palapattu; Amiel E Gilad; Yair Lotan; Craig G Rogers; Amnon Vazina; Amit Gupta; Patrick J Bastian; Paul Perrotte; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
The Journal of urology 2006;176(4 Pt 1):1354-61; discussion 1361-2.
2006: Robert S Svatek; Yair Lotan; Michael P Herman; Michael Hermann; David A Duchene; Arthur I Sagalowsky; Jeffrey A Cadeddu
The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma.
The Journal of urology 2006;176(4 Pt 1):1321-5; discussion 125.
2006: Lance Walsh; Jennifer Stanfield; L Chinsoo Cho; Cheng-Hui Chang; Kenneth Forster; Wareef Kabbani; Jeffrey A Cadeddu; Jer-Tsong Hsieh; Hak Choy; Robert D Timmerman; Yair Lotan
Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model.
European urology 2006;50(4):795-800; discussion 800.
2006: Shahrokh F Shariat; Ganesh S Palapattu; Gilad E Amiel; Pierre I Karakiewicz; Craig G Rogers; Amnon Vazina; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Yair Lotan
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy.
Urology 2006;68(3):538-42.
2006: Shahrokh F Shariat; Michael Marberger; Yair Lotan; Marta Sanchez-Carbayo; Craig D Zippe; Gerson Lüdecke; Hans Boman; Ihor S Sawczuk; Martin G Friedrich; Roberto Casella; Christine Mian; Sanaa Eissa; Hideyuki Akaza; Vincenzo Serretta; Hartwig Huland; Hans Hedelin; Rupesh Raina; Naoto Miyanaga; Arthur I Sagalowsky; Claus G Roehrborn; Pierre I Karakiewicz
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
The Journal of urology 2006;176(3):919-26; discussion 926.
2006: Yair Lotan; Robert S Svatek; Arthur I Sagalowsky
Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Cancer 2006;107(5):982-90.
2006: Sangtae Park; J Kyle Anderson; Edward D Matsumoto; Yair Lotan; Shellie C Josephs; Jeffrey A Cadeddu
Radiofrequency ablation of renal tumors: intermediate-term results.
Journal of endourology / Endourological Society 2006;20(8):569-73.
2006: Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
The cost of prostate cancer chemoprevention: a decision analysis model.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(8):1485-9.
2006: Robert S Svatek; Arthur I Sagalowsky; Yair Lotan
Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.
Urologic oncology 2006;24(4):338-43.
2006: Craig G Rogers; Ganesh S Palapattu; Shahrokh F Shariat; Pierre I Karakiewicz; Patrick J Bastian; Yair Lotan; Amit Gupta; Amnon Vazina; Amiel Gilad; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
The Journal of urology 2006;175(6):2048-53; discussion 2053.
2006: Yair Lotan; Jennifer Stanfield; L Chinsoo Cho; Jennifer B Sherwood; Khaled F Abdel-Aziz; Cheng-Hui Chang; Kenneth Forster; Wareef Kabbani; Jer-Tsong Hsieh; Hak Choy; Robert D Timmerman
Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model.
The Journal of urology 2006;175(5):1932-6.
2006: Ganesh S Palapattu; Shahrokh F Shariat; Pierre I Karakiewicz; Patrick J Bastian; Craig G Rogers; Gilad E Amiel; Yair Lotan; Amnon Vazina; Amit Gupta; Arthur I Sagalowsky; Seth P Lerner; Mark P Schoenberg
Cancer specific outcomes in patients with pT0 disease following radical cystectomy.
The Journal of urology 2006;175(5):1645-9; discussion 1649.
2006: Robert S Svatek; Michael P Herman; Yair Lotan; Roberto Casella; Jer-Tsong Hsieh; Arthur I Sagalowsky; Shahrokh F Shariat
Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Cancer 2006;106(8):1701-7.
2006: Claus G Roehrborn; Yair Lotan; Andrea Tubaro; Cosimo de Nunzio
Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
European urology 2006;49(2):396-400.
2006: Shahrokh F Shariat; Khaled F Abdel-Aziz; Claus G Roehrborn; Yair Lotan
Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
European urology 2006;49(2):293-302.
2005: Shahrokh F Shariat; David A Duchene; Wareef Kabbani; Zachary Mucher; Yair Lotan
Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor.
Urology 2005;66(6):1319.
2005: Shahrokh F Shariat; Raheela Ashfaq; Claus G Roehrborn; Kevin Slawin; Yair Lotan
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
The Journal of urology 2005;174(5):2046-50.
2005: Yair Lotan; Amit Gupta; Shahrokh F Shariat; Ganesh S Palapattu; Amnon Vazina; Pierre I Karakiewicz; Patrick J Bastian; Craig G Rogers; Gilad E Amiel; Paul Perotte; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6533-9.
2005: J Kyle Anderson; Adam Murdock; Jeffrey A Cadeddu; Yair Lotan
Cost comparison of laparoscopic versus radical retropubic prostatectomy.
Urology 2005;66(3):557-60.
2005: Shahrokh F Shariat; Michael P Herman; Roberto Casella; Yair Lotan; Jose A Karam; Ulf-Hakan Stenman
Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
European urology 2005;48(3):424-31.
2005: Vitaly Margulis; Edward D Matsumoto; Robert S Svatek; Wareef Kabbani; Jeffrey A Cadeddu; Yair Lotan
Application of novel hemostatic agent during laparoscopic partial nephrectomy.
The Journal of urology 2005;174(2):761-4.
2005: Robert S Svatek; David Lee; Yair Lotan
Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?
Urology 2005;66(1):65-8.
2005: Yair Lotan; Jeffrey A Cadeddu; Margaret S Pearle
International comparison of cost effectiveness of medical management strategies for nephrolithiasis.
Urological research 2005;33(3):223-30.
2005: S Alexis Gordon; Key H Stage; Keith E Tansey; Yair Lotan
Conservative management of priapism in acute spinal cord injury.
Urology 2005;65(6):1195-7.
2005: Yair Lotan; Jeffrey A Cadeddu
A cost comparison of nephron-sparing surgical techniques for renal tumour.
BJU international 2005;95(7):1039-42.
2005: Shahrokh F Shariat; Craig D Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Ihor S Sawczuk; Vincenzo Serretta; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Frank H Wians; Claus G Roehrborn; Yair Lotan; Paul Perrotte; Serge Benayoun; Michael Marberger; Pierre I Karakiewicz
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
The Journal of urology 2005;173(5):1518-25.
2005: Yair Lotan; Jeffrey A Cadeddu; J Jack Lee; Claus G Roehrborn; Scott M Lippman
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1911-20.
2004: Yair Lotan; Jeffrey A Cadeddu; Claus G Roerhborn; Charles Y C Pak; Margaret S Pearle
Cost-effectiveness of medical management strategies for nephrolithiasis.
The Journal of urology 2004;172(6 Pt 1):2275-81.
2004: Yair Lotan; Jeffrey A Cadeddu; Claus G Roehrborn; Key H Stage
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology.
The Journal of urology 2004;172(5 Pt 1):1958-62.
2004: Yair Lotan; Jeffrey A Cadeddu; Matthew T Gettman
The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques.
The Journal of urology 2004;172(4 Pt 1):1431-5.
2004: Armando J Lorenzo; Mindy L Samuelson; Steven G Docimo; Linda A Baker; Yair Lotan
Cost analysis of laparoscopic versus open orchiopexy in the management of unilateral nonpalpable testicles.
The Journal of urology 2004;172(2):712-6.
2004: Seyed M Khoddami; Shahrokh F Shariat; Yair Lotan; Hossein Saboorian; John D McConnell; Arthur I Sagalowsky; Claus G Roehrborn; Kenneth S Koeneman
Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.
BJU international 2004;94(1):42-6.
2004: Yair Lotan; Shahrokh F Shariat; Seyed M Khoddami; Hossein Saboorian; Kenneth S Koeneman; Jeffrey A Cadeddu; Arthur I Sagalowsky; John D McConnell; Claus G Roehrborn
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
The Journal of urology 2004;171(6 Pt 1):2209-14.
2004: Yair Lotan; David A Duchene; Jeffrey A Cadeddu; Arthur I Sagalowsky; Kenneth S Koeneman
Changing management of organ-confined renal masses.
Journal of endourology / Endourological Society 2004;18(3):263-8.
2004: Shahrokh F Shariat; Yair Lotan; Hossein Saboorian; Seyed M Khoddami; Claus G Roehrborn; Kevin Slawin; Raheela Ashfaq
Survivin expression is associated with features of biologically aggressive prostate carcinoma.
Cancer 2004;100(4):751-7.
2004: Yair Lotan; Matthew T Gettman; Guy Lindberg; Cheryl Napper; John Hoopman; Margaret S Pearle; Jeffrey A Cadeddu
Laparoscopic partial nephrectomy using holmium laser in a porcine model.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2004;8(1):51-5.
2003: D Brooke Johnson; Grant D Taylor; Yair Lotan; Arthur I Sagalowsky; Kenneth S Koenemann; Jeffrey A Cadeddu
The effects of radio frequency ablation on renal function and blood pressure.
The Journal of urology 2003;170(6 Pt 1):2234-6.
2003: Yair Lotan; Claus G Roehrborn; John D McConnell; Benjamin N Hendin
Factors influencing the outcomes of penile prosthesis surgery at a teaching institution.
Urology 2003;62(5):918-21.
2003: David A Duchene; Yair Lotan; Jeffrey A Cadeddu; Arthur I Sagalowsky; Kenneth S Koeneman
Histopathology of surgically managed renal tumors: analysis of a contemporary series.
Urology 2003;62(5):827-30.
2003: Yair Lotan; David A Duchene; Jeffrey A Cadeddu; Kenneth S Koeneman
Cost comparison of hand assisted laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters.
The Journal of urology 2003;170(3):752-5.
2003: Matthew T Gettman; Yair Lotan; Jeffrey A Cadeddu
Laparoscopic treatment of ovarian vein syndrome.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2003;7(3):257-60.
2003: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Margaret S Pearle; Jeffrey A Cadeddu
Laparoscopic nephrectomy is cost effective compared with open nephrectomy in a large county hospital.
JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons 2003;7(2):111-5.
2003: Yair Lotan; Claus G Roehrborn
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.
Urology 2003;61(1):109-18; discussion 118.
2003: Matthew T Gettman; Yair Lotan; Claus G Roerhborn; Jeffrey A Cadeddu; Margaret S Pearle
Cost-effective treatment for ureteropelvic junction obstruction: a decision tree analysis.
The Journal of urology 2003;169(1):228-32.
2002: Kenneth Ogan; David M Wilhelm; Guy Lindberg; Yair Lotan; Cheryl Napper; John Hoopman; Margaret S Pearle; Jeffrey A Cadeddu
Laparoscopic partial nephrectomy with a diode laser: porcine results.
Journal of endourology / Endourological Society 2002;16(10):749-53.
2002: Kenneth Ogan; Yair Lotan; Kenneth S Koeneman; Margaret S Pearle; Jeffrey A Cadeddu; Jens Rassweiler
Laparoscopic versus open retroperitoneal lymph node dissection: a cost analysis.
The Journal of urology 2002;168(5):1945-9; discussion 1949.
2002: Matthew T Gettman; Yair Lotan; Guy Lindberg; Cheryl Napper; John Hoopman; Margaret S Pearle; Jeffrey A Cadeddu
Laparoscopic interstitial laser coagulation of renal tissue with and without hilar occlusion in the porcine model.
Journal of endourology / Endourological Society 2002;16(8):565-70.
2002: Yair Lotan; Matthew T Gettman; Kenneth Ogan; Linda A Baker; Jeffrey A Cadeddu
Clinical use of the holmium: YAG laser in laparoscopic partial nephrectomy.
Journal of endourology / Endourological Society 2002;16(5):289-92.
2002: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Margaret S Pearle; Jeffrey A Cadeddu
Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters.
Urology 2002;59(6):821-5.
2002: Yair Lotan; Matthew T Gettman; Claus G Roehrborn; Jeffrey A Cadeddu; Margaret S Pearle
Management of ureteral calculi: a cost comparison and decision making analysis.
The Journal of urology 2002;167(4):1621-9.
2002: Matthew T Gettman; Yair Lotan; T Spark Corwin; Thomas G Smith; Cheryl Napper; Guy Lindberg; Jeffrey A Cadeddu
Radiofrequency coagulation of renal parenchyma: comparison of effects of energy generators on treatment efficacy.
Journal of endourology / Endourological Society 2002;16(2):83-8.
2002: Matthew T Gettman; Yair Lotan; Cheryl Napper; Jeffrey A Cadeddu
Transvaginal laparoscopic nephrectomy: development and feasibility in the porcine model.
Urology 2002;59(3):446-50.
2002: Yair Lotan; Claus G Roehrborn
Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
The Journal of urology 2002;167(1):75-9.